肺癌免疫治疗的现状和未来展望

Current and future of immunotherapy in lung cancer

针对PD-1/PD-L1的免疫治疗显著延长了晚期肺癌患者的生存,已成为晚期肺癌一线、二线的标准治疗选择。但目前,在临床应用中仍存在很多不足,如有效率不高、获益人群有限、缺乏精准的标志物等问题。针对免疫治疗的这些问题,更多的新的免疫治疗模式和新的治疗靶点不断被探索并应用,如新的免疫联合治疗模式,新的免疫治疗靶点等,成为未来免疫治疗的方向。

Checkpoint inhibitors targeting PD-1/PD-L1 have achieved substantial overall survival improvement in advanced Non-small cell lung cancer and have been approved for standard first line and second line treatment.Shortcomings such as low overall response rate,limited beneficial population,lack of precise predictive biomarkers still exist in clinical practice.More combination strategies and more novel therapeutic targets have been investigated and it might be the prospect of immunotherapeutic treatment in future.